Current Report Filing (8-k)
November 14 2018 - 3:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 14, 2018
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36570
|
|
45-4488360
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
34790 Ardentech Court
Fremont, CA 94555
(Address of principal executive offices) (Zip Code)
(510)
745-1200
Registrants telephone number, including area code
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communication pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communication pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 2.02
|
Results of Operations and Financial Conditions.
|
On November 14, 2018, we issued a press released titled Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational
Update. The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference into this Item 2.02.
The information in Item 2.02 of this Form
8-K
(including Exhibit 99.1) shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION
|
|
|
|
|
Dated: November 14, 2018
|
|
|
|
By:
|
|
/s/ John Walker
|
|
|
|
|
|
|
Name: John Walker
|
|
|
|
|
|
|
Title: President and Chief Executive Officer
|
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2024 to May 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Zosano Pharma Corporation (NASDAQ): 0 recent articles
More Zosano Pharma Corp News Articles